Accendra Health Q2 profit, revenue miss estimates on large payor exit
ACH•Analyst coverage
- The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"
- The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
- Wall Street's median 12-month price target for Accendra Health Inc is $4.50, about 60.7% above its August 7 closing price of $2.80
- The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago
Quarterly results miss estimates
- US home healthcare firm's Q2 revenue fell and missed analyst expectations
- Adjusted loss per share and adjusted EBITDA for Q2 both missed analyst expectations
- Company reduced total debt by $385 mln
- Company says CEO Ed Pesicka to retire by end-2026
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Revenue | Miss | $613.20 mln | $627.31 mln (6 Analysts) |
| Q2 Adjusted Loss Per Share | Miss | $0.19 | $0.09 (6 Analysts) |
| Q2 Net Loss | $89.07 mln | ||
| Q2 Adjusted EBITDA | Miss | $60.10 mln | $61.32 mln (6 Analysts) |
